Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Designing an Inclusive Onboarding Program for Academic Ambulatory Care Faculty

Bilek A, Rabbani A, Wampande J, Pregler J. Designing an Inclusive Onboarding Program for Academic Ambulatory Care Faculty. Cureus. 2025 Jun 4;17(6):e85356. doi: 10.7759/cureus.85356. PMID:[...]

Hospital Patient Experience Worsened With the COVID-19 Pandemic, Especially for Older Adults, and Remains Worse than Before

Beckett MK, W Cohea C, Saliba D, Cleary PD, A Giordano L, Elliott MN. Hospital Patient Experience Worsened With the COVID-19 Pandemic, Especially for Older[...]

Deep Learning Multi Modal Melanoma Detection: Algorithm Development and Validation

Vivek N, Ramesh K. Deep Learning Multi Modal Melanoma Detection: Algorithm Development and Validation. JMIR AI. 2025 Jul 5. doi: 10.2196/66561. Epub ahead of print.[...]